BioCentury
ARTICLE | Clinical News

UCB's bimekizumab meets in Phase IIb for ankylosing spondylitis

December 22, 2017 7:52 PM UTC

UCB S.A. (Euronext:UCB) reported data from the Phase IIb BE AGILE trial in 303 patients with active ankylosing spondylitis showing that subcutaneous bimekizumab (UCB4940) every four weeks met the primary endpoint of a greater proportion of patients who achieved a 40% improvement in Assessment of SpondyloArthritis International Society criteria (ASAS40) at week 12 vs. placebo. UCB said up to 47% of patients who received bimekizumab achieved an ASAS40 response at week 12 compared to 13% of patients who received placebo. Bimekizumab was generally well tolerated.

Secondary endpoints in the double-blind, international trial include Ankylosing Spondylitis Disease Activity Score-C-Reactive Protein (ASDAS-CRP), ASAS20, ASAS5/6, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis Function Index (BASFI). Patients received placebo or one of five dose regimens of bimekizumab for 12 weeks, after which all patients were re-randomized to a dose-blinded bimekizumab treatment arm for 36 weeks. ...

BCIQ Company Profiles

UCB S.A.

BCIQ Target Profiles

IL-17A

IL-17F